deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03689894

Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant

Sponsor: Dartmouth-Hitchcock Medical Center

Conditions Chronic Graft-versus-host-disease
Interventions Ibrutinib Rituximab
Updated 12 times since 2018 Last updated: Nov 3, 2023 Started: Apr 11, 2019 Primary completion: Sep 20, 2021 Completion: Sep 20, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient accrual

Other terminated trials from Dartmouth-Hitchcock Medical Center

See all terminations from Dartmouth-Hitchcock Medical Center

Other Chronic Graft-versus-host-disease trials with similar outcome

Browse all Chronic Graft-versus-host-disease trials

Listed as NCT03689894, this PHASE1/PHASE2 trial focuses on Chronic Graft-versus-host-disease and remains terminated or withdrawn. Sponsored by Dartmouth-Hitchcock Medical Center, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshotNot Yet Recruiting~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshotNot Yet Recruiting~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2019 – ~May 2019 · 2 months · monthly snapshotNot Yet Recruiting~May 2019 – ~Sep 2019 · 4 months · monthly snapshotRecruiting~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshotRecruiting~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotRecruiting~Nov 2021 – ~Dec 2023 · 25 months · monthly snapshotTerminated~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Nov 2021 — Dec 2023 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  3. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Mar 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE1

  5. Feb 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE1

  6. Dec 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE1

  7. Nov 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dartmouth-Hitchcock Medical Center
Data source: Dartmouth-Hitchcock Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations